Explore igf-1 lr3 calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.
Anonymized igf-1 lr3 calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.
IGF-1 LR3 (Long Arg³ IGF-1) is an insulin-like-growth-factor analog most often sourced in bodybuilding and recomposition research; it was originally made as a cell-culture reagent, not a human therapy. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1]
The Glu³→Arg substitution dramatically reduces affinity for the six IGF-binding proteins (IGFBPs) that normally sequester ~99% of circulating IGF-1, while the N-terminal extension preserves binding to the IGF-1 receptor. The combined effect is that IGF-1 LR3 retains roughly 30% of native IGF-1's receptor affinity but exhibits 2–3× greater in vivo bioactivity and a longer functional half-life because it is not buffered by IGFBPs.[2]
IGF-1 LR3 is sold by major life-sciences suppliers (Sigma-Aldrich, Repligen, GroPep) as an animal-component-free supplement for CHO and hybridoma cell cultures used in biologics manufacturing.[3] No clinical-trial sponsor has ever pursued human therapeutic development; the molecule is explicitly not intended for human use, and the World Anti-Doping Agency lists IGF-1 LR3 as a prohibited substance.
Not FDA-approved for any human indication; sold strictly as a research / cell-culture reagent. Banned by the World Anti-Doping Agency under S2 (Peptide Hormones, Growth Factors).
IGF-1 LR3 has a reported half-life of ~20–30 hours. The pharmacokinetic reference models an interval of once daily; this is not a measured community cadence or a dosing recommendation. Reduced IGF-binding-protein affinity gives LR3 a much longer half-life than native IGF-1, so daily dosing produces real day-to-day buildup over the first few days. Pharmacokinetic source: Pre-clinical / manufacturer estimates (~20–30 h commonly cited). It is catalogued under Muscle Peptides on WPA.
684 IGF-1 LR3 reconstitution calculations have been logged by the WPA community.
This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
WPA Analysis
IGF-1 LR3 — Long Arg3 Insulin-like Growth Factor 1 — is one of the more interesting non-pharmaceutical molecules on this site, because it was never engineered as a human therapeutic. It was developed at GroPep Ltd in Adelaide, Australia in the late 1980s as a recombinant cell-culture reagent: the molecule is native human IGF-1 with a 13-amino-acid N-terminal extension and an arginine substitution at position 3, two engineering choices that together dramatically reduce binding to the IGF-binding proteins (IGFBPs) that normally tie up the vast majority of circulating IGF-1 in serum. The biological rationale is straight pharmacology: free IGF-1 is the bioactive fraction, IGFBP-3 alone binds about 75% of total IGF-1 in plasma, and an engineered variant that escapes IGFBP capture is more potent on a milligram-for-milligram basis and stays in circulation longer. The Tomas et al. work at GroPep through the early 1990s ("Long-R3-IGF-I, an analogue of IGF-I, has potent anabolic effects in cultured cells and in vivo in rats") characterized the variant's pharmacokinetic and anabolic profile, and the molecule went on to become a standard cell-culture additive in biotech research — used in mammalian-cell bioprocessing, stem-cell media, and tissue-engineering work where a long-acting, IGFBP-resistant IGF-1 stimulus is needed.
The critical caveat for any researcher working with IGF-1 LR3 is that the molecule has no approved human therapeutic indication anywhere in the world, and the published human pharmacokinetic data is essentially restricted to small early-stage studies in growth-disorder populations using native recombinant IGF-1 (mecasermin, Increlex) rather than the LR3 variant. Mecasermin itself carries an FDA-labeled indication only for severe primary IGF-1 deficiency in pediatric patients, and its label requires close monitoring for hypoglycemia — a real concern given IGF-1's structural similarity to insulin and its measurable insulin-like effects on peripheral glucose uptake.
Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.
WPA DOSING INSIGHT
The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.
WPA RECONSTITUTION INSIGHT
Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.